Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 98, Issue 2, Pages 145-161Publisher
WILEY
DOI: 10.1002/cpt.143
Keywords
-
Categories
Funding
- National Institutes of Health [K08DK101602]
Ask authors/readers for more resources
Cardiovascular disease is the principal complication and the leading cause of death for patients with diabetes (DM). The efficacy of antihyperglycemic treatments on cardiovascular disease risk remains uncertain. Cardiovascular risk factors are affected by antihyperglycemic medications, as are many intermediate markers of cardiovascular disease. Here we summarize the evidence assessing the cardiovascular effects of antihyperglycemic medications with regard to risk factors, intermediate markers of disease, and clinical outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available